BB Biotech Update February 2021

We are seeing continued progress with the SARS-CoV-2 vaccine rollouts. In the US almost 20% of the population has received one or more doses of a SARS-CoV-2 vaccine. BB Biotech´s portfolio company Moderna is still one of the leaders in the vaccines field with their mRNA-1273 vaccine being distributed widely. February was a volatile month for both the biotech sector and BB Biotech with a strong start to the month and then a downturn by the end of February. We continue to see positive fundamental developments in our portfolio companies. On February 19, BB Biotech published its Annual Report 2020 in a digital format – the report can be read here: https://report.bbbiotech.ch/2020/en/